Sabby Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Sabby Management’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-16,042	Closed	-$652K	–	159
2020 Q3	$652K	Buy	+16,042	New	+$631K	0.1%	75
2018 Q2	–	Sell	-190	Closed	-$87K	–	195
2018 Q1	$87K	Sell	190 -683	-78%	-$339K	0.01%	136
2017 Q4	$503K	Buy	+873	New	+$575K	0.05%	102
2013 Q4	–	Sell	-185	Closed	-$727K	–	251
2013 Q3	$727K	Buy	+185	New	+$1.39M	0.05%	139

Other funds holding FRTX

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Sabby Management's FRTX Position: Q4 2020 in Review

Sabby Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2020, closing a stake of 16,042 shares — an estimated $652K sold.

Sabby Management first reported a position in FRTX in Q3 2013 and held it in 4 quarters. The position peaked at $727K in Q3 2013. 25 funds tracked by Wall St. Rank hold FRTX as of Q4 2020.

Sabby Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Sabby Management sold 16,042 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $652K.
Sabby Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2013 and held it in 4 quarters.
Sabby Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $727K in Q3 2013.
25 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.